Dexcom Inc
NASDAQ:DXCM
Dexcom Inc
Stock-Based Compensation
Dexcom Inc
Stock-Based Compensation Peer Comparison
Competitive Stock-Based Compensation Analysis
Latest Figures & CAGR of Competitors
Company | Stock-Based Compensation | CAGR 3Y | CAGR 5Y | CAGR 10Y | |
---|---|---|---|---|---|
Dexcom Inc
NASDAQ:DXCM
|
Stock-Based Compensation
$154.6m
|
CAGR 3-Years
8%
|
CAGR 5-Years
9%
|
CAGR 10-Years
19%
|
|
Becton Dickinson and Co
NYSE:BDX
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Boston Scientific Corp
NYSE:BSX
|
Stock-Based Compensation
$241m
|
CAGR 3-Years
11%
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Stryker Corp
NYSE:SYK
|
Stock-Based Compensation
$218m
|
CAGR 3-Years
12%
|
CAGR 5-Years
12%
|
CAGR 10-Years
11%
|
|
Abbott Laboratories
NYSE:ABT
|
Stock-Based Compensation
N/A
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
Intuitive Surgical Inc
NASDAQ:ISRG
|
Stock-Based Compensation
$606.3m
|
CAGR 3-Years
14%
|
CAGR 5-Years
17%
|
CAGR 10-Years
13%
|
See Also
What is Dexcom Inc's Stock-Based Compensation?
Stock-Based Compensation
154.6m
USD
Based on the financial report for Mar 31, 2024, Dexcom Inc's Stock-Based Compensation amounts to 154.6m USD.
What is Dexcom Inc's Stock-Based Compensation growth rate?
Stock-Based Compensation CAGR 10Y
19%
Over the last year, the Stock-Based Compensation growth was 17%. The average annual Stock-Based Compensation growth rates for Dexcom Inc have been 8% over the past three years , 9% over the past five years , and 19% over the past ten years .